Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 18 | 2022 | 438 | 5.670 |
Why?
|
Colorectal Neoplasms | 39 | 2024 | 613 | 4.660 |
Why?
|
Early Detection of Cancer | 32 | 2025 | 501 | 4.160 |
Why?
|
Colonoscopy | 20 | 2024 | 251 | 2.580 |
Why?
|
Survivors | 6 | 2018 | 149 | 2.510 |
Why?
|
Breast Neoplasms | 22 | 2020 | 949 | 2.300 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2018 | 244 | 2.170 |
Why?
|
Mass Screening | 20 | 2024 | 661 | 2.000 |
Why?
|
Humans | 96 | 2025 | 17611 | 1.950 |
Why?
|
Aged | 66 | 2025 | 6095 | 1.910 |
Why?
|
Middle Aged | 63 | 2025 | 7911 | 1.610 |
Why?
|
Electronic Health Records | 7 | 2023 | 681 | 1.560 |
Why?
|
Occult Blood | 13 | 2024 | 153 | 1.560 |
Why?
|
Algorithms | 5 | 2020 | 233 | 1.510 |
Why?
|
Female | 73 | 2025 | 12608 | 1.500 |
Why?
|
Cancer Survivors | 3 | 2022 | 83 | 1.460 |
Why?
|
Health Services Research | 4 | 2016 | 231 | 1.350 |
Why?
|
Adaptation, Psychological | 4 | 2018 | 77 | 1.310 |
Why?
|
Guideline Adherence | 4 | 2025 | 155 | 1.170 |
Why?
|
Male | 45 | 2024 | 10008 | 1.100 |
Why?
|
Animal Assisted Therapy | 2 | 2017 | 5 | 1.100 |
Why?
|
Child, Hospitalized | 2 | 2017 | 14 | 1.090 |
Why?
|
Aged, 80 and over | 22 | 2024 | 1900 | 1.090 |
Why?
|
Washington | 17 | 2020 | 374 | 1.050 |
Why?
|
Antidepressive Agents | 3 | 2015 | 155 | 1.020 |
Why?
|
Adenoma | 7 | 2024 | 93 | 0.980 |
Why?
|
Uterine Cervical Neoplasms | 5 | 2025 | 119 | 0.940 |
Why?
|
Risk Factors | 19 | 2023 | 3325 | 0.910 |
Why?
|
Practice Guidelines as Topic | 7 | 2025 | 318 | 0.900 |
Why?
|
United States | 19 | 2024 | 3956 | 0.880 |
Why?
|
Comparative Effectiveness Research | 3 | 2013 | 66 | 0.850 |
Why?
|
Postmenopause | 7 | 2009 | 241 | 0.840 |
Why?
|
Epidemiologic Methods | 2 | 2012 | 81 | 0.810 |
Why?
|
Adult | 25 | 2025 | 7598 | 0.800 |
Why?
|
Bias | 4 | 2022 | 102 | 0.770 |
Why?
|
Diabetes Mellitus | 2 | 2018 | 487 | 0.750 |
Why?
|
Colonic Neoplasms | 2 | 2019 | 155 | 0.740 |
Why?
|
Neoplasms, Second Primary | 4 | 2018 | 29 | 0.720 |
Why?
|
Quality of Life | 4 | 2018 | 507 | 0.700 |
Why?
|
Delivery of Health Care, Integrated | 8 | 2017 | 531 | 0.700 |
Why?
|
Return to Work | 1 | 2019 | 2 | 0.680 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2019 | 6 | 0.680 |
Why?
|
Patient Acceptance of Health Care | 4 | 2022 | 382 | 0.670 |
Why?
|
Follow-Up Studies | 10 | 2020 | 1210 | 0.660 |
Why?
|
Surveys and Questionnaires | 8 | 2019 | 1309 | 0.650 |
Why?
|
Adenocarcinoma | 4 | 2022 | 172 | 0.650 |
Why?
|
Proportional Hazards Models | 6 | 2019 | 709 | 0.650 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2019 | 55 | 0.640 |
Why?
|
Age Factors | 5 | 2024 | 917 | 0.610 |
Why?
|
Papillomavirus Infections | 3 | 2025 | 133 | 0.590 |
Why?
|
Liver Cirrhosis | 1 | 2017 | 35 | 0.580 |
Why?
|
Sensitivity and Specificity | 6 | 2022 | 304 | 0.580 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2017 | 26 | 0.580 |
Why?
|
Health Expenditures | 1 | 2018 | 75 | 0.570 |
Why?
|
Time Factors | 6 | 2019 | 1086 | 0.560 |
Why?
|
Liver Neoplasms | 1 | 2017 | 40 | 0.560 |
Why?
|
Cohort Studies | 14 | 2025 | 2570 | 0.540 |
Why?
|
Anticarcinogenic Agents | 1 | 2016 | 13 | 0.540 |
Why?
|
Feces | 2 | 2016 | 80 | 0.530 |
Why?
|
Reproducibility of Results | 2 | 2015 | 381 | 0.530 |
Why?
|
Patient Satisfaction | 1 | 2017 | 211 | 0.530 |
Why?
|
Employment | 1 | 2016 | 42 | 0.530 |
Why?
|
Oncology Service, Hospital | 1 | 2015 | 1 | 0.530 |
Why?
|
Bonding, Human-Pet | 1 | 2015 | 2 | 0.530 |
Why?
|
Endometrial Neoplasms | 2 | 2007 | 35 | 0.520 |
Why?
|
Colonic Polyps | 3 | 2023 | 34 | 0.520 |
Why?
|
Research | 2 | 2013 | 64 | 0.520 |
Why?
|
Paroxetine | 1 | 2015 | 23 | 0.520 |
Why?
|
Aspirin | 1 | 2016 | 63 | 0.520 |
Why?
|
Mammography | 3 | 2015 | 169 | 0.510 |
Why?
|
Population Surveillance | 1 | 2017 | 263 | 0.510 |
Why?
|
Primary Prevention | 1 | 2016 | 73 | 0.510 |
Why?
|
Insurance Coverage | 1 | 2016 | 106 | 0.500 |
Why?
|
Uterine Cervical Dysplasia | 3 | 2025 | 8 | 0.500 |
Why?
|
Psychometrics | 1 | 2015 | 121 | 0.490 |
Why?
|
Antidepressive Agents, Tricyclic | 2 | 2013 | 9 | 0.480 |
Why?
|
Insurance, Health | 1 | 2016 | 181 | 0.480 |
Why?
|
Retrospective Studies | 13 | 2023 | 2447 | 0.480 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 330 | 0.470 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2012 | 53 | 0.470 |
Why?
|
Professional Role | 1 | 2013 | 10 | 0.460 |
Why?
|
Epidemiologic Studies | 1 | 2013 | 29 | 0.440 |
Why?
|
Delivery of Health Care | 6 | 2022 | 415 | 0.440 |
Why?
|
Medical Oncology | 1 | 2013 | 32 | 0.440 |
Why?
|
Depressive Disorder | 1 | 2015 | 222 | 0.440 |
Why?
|
Cardiovascular Diseases | 2 | 2016 | 598 | 0.430 |
Why?
|
Preventive Medicine | 1 | 2013 | 24 | 0.430 |
Why?
|
Behavioral Sciences | 1 | 2012 | 2 | 0.430 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 130 | 0.420 |
Why?
|
Health Personnel | 1 | 2013 | 124 | 0.410 |
Why?
|
Reminder Systems | 5 | 2017 | 80 | 0.410 |
Why?
|
Health Status Indicators | 1 | 2012 | 64 | 0.400 |
Why?
|
Heart Diseases | 1 | 2012 | 77 | 0.390 |
Why?
|
Health Policy | 1 | 2012 | 122 | 0.390 |
Why?
|
Logistic Models | 6 | 2018 | 926 | 0.360 |
Why?
|
Serotonin Uptake Inhibitors | 1 | 2011 | 71 | 0.360 |
Why?
|
Registries | 6 | 2019 | 471 | 0.360 |
Why?
|
Databases, Factual | 1 | 2011 | 309 | 0.350 |
Why?
|
Animals | 3 | 2017 | 259 | 0.350 |
Why?
|
Postal Service | 5 | 2019 | 72 | 0.340 |
Why?
|
Drug Prescriptions | 1 | 2011 | 151 | 0.340 |
Why?
|
Exercise | 4 | 2007 | 489 | 0.330 |
Why?
|
Histamine H2 Antagonists | 1 | 2009 | 13 | 0.330 |
Why?
|
Proton Pump Inhibitors | 1 | 2009 | 24 | 0.330 |
Why?
|
Disease Progression | 3 | 2016 | 264 | 0.330 |
Why?
|
Young Adult | 10 | 2025 | 2427 | 0.330 |
Why?
|
Case-Control Studies | 8 | 2023 | 1115 | 0.320 |
Why?
|
Patient Compliance | 4 | 2017 | 298 | 0.320 |
Why?
|
Breast | 1 | 2009 | 84 | 0.310 |
Why?
|
Health Care Costs | 1 | 2010 | 228 | 0.310 |
Why?
|
Estrogens | 2 | 2007 | 61 | 0.300 |
Why?
|
Research Design | 5 | 2013 | 374 | 0.300 |
Why?
|
Predictive Value of Tests | 3 | 2013 | 351 | 0.290 |
Why?
|
Progestins | 1 | 2007 | 25 | 0.290 |
Why?
|
Estrogen Replacement Therapy | 1 | 2007 | 99 | 0.280 |
Why?
|
Colposcopy | 2 | 2023 | 4 | 0.280 |
Why?
|
Dogs | 2 | 2017 | 17 | 0.280 |
Why?
|
Lung Neoplasms | 3 | 2022 | 255 | 0.280 |
Why?
|
Thinness | 1 | 2006 | 30 | 0.270 |
Why?
|
Odds Ratio | 6 | 2019 | 671 | 0.260 |
Why?
|
Bone Density | 1 | 2006 | 92 | 0.260 |
Why?
|
Hospitals, Pediatric | 2 | 2017 | 79 | 0.260 |
Why?
|
Neoplasm Staging | 7 | 2017 | 325 | 0.250 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 250 | 0.250 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2018 | 63 | 0.250 |
Why?
|
Adolescent | 6 | 2019 | 3651 | 0.250 |
Why?
|
Patient Navigation | 2 | 2015 | 14 | 0.240 |
Why?
|
SEER Program | 5 | 2020 | 91 | 0.240 |
Why?
|
Anxiety | 2 | 2018 | 150 | 0.240 |
Why?
|
Follicle Stimulating Hormone | 1 | 2004 | 2 | 0.240 |
Why?
|
Estradiol | 1 | 2004 | 23 | 0.240 |
Why?
|
Sex Hormone-Binding Globulin | 1 | 2004 | 22 | 0.240 |
Why?
|
Risk Assessment | 5 | 2019 | 1097 | 0.240 |
Why?
|
Patient-Centered Care | 2 | 2016 | 197 | 0.220 |
Why?
|
Vaginal Smears | 4 | 2025 | 48 | 0.220 |
Why?
|
Biomarkers, Tumor | 1 | 2004 | 142 | 0.220 |
Why?
|
Survival Rate | 2 | 2013 | 260 | 0.210 |
Why?
|
Primary Health Care | 3 | 2022 | 766 | 0.200 |
Why?
|
Reproductive History | 2 | 2017 | 17 | 0.200 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 1322 | 0.200 |
Why?
|
Tamoxifen | 2 | 2018 | 56 | 0.180 |
Why?
|
Intestinal Polyps | 1 | 2020 | 7 | 0.180 |
Why?
|
Patient Selection | 2 | 2012 | 190 | 0.170 |
Why?
|
Prostatic Neoplasms | 1 | 2022 | 262 | 0.170 |
Why?
|
Interviews as Topic | 2 | 2013 | 305 | 0.170 |
Why?
|
Symptom Assessment | 1 | 2019 | 6 | 0.170 |
Why?
|
Child | 2 | 2017 | 2474 | 0.170 |
Why?
|
Linear Models | 3 | 2011 | 231 | 0.170 |
Why?
|
Papillomaviridae | 3 | 2025 | 52 | 0.170 |
Why?
|
Socioeconomic Factors | 3 | 2019 | 630 | 0.160 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2018 | 1 | 0.160 |
Why?
|
Educational Status | 1 | 2019 | 200 | 0.160 |
Why?
|
Motivation | 1 | 2019 | 130 | 0.160 |
Why?
|
Evidence-Based Medicine | 1 | 2019 | 185 | 0.150 |
Why?
|
Diabetes Complications | 1 | 2018 | 114 | 0.150 |
Why?
|
Healthcare Disparities | 2 | 2019 | 201 | 0.150 |
Why?
|
Pediatric Nursing | 1 | 2017 | 3 | 0.150 |
Why?
|
Incidence | 2 | 2016 | 1255 | 0.150 |
Why?
|
Ultrasonography | 1 | 2017 | 35 | 0.150 |
Why?
|
Nurses | 2 | 2015 | 36 | 0.140 |
Why?
|
Contraceptives, Oral | 1 | 2017 | 26 | 0.140 |
Why?
|
Comorbidity | 2 | 2016 | 594 | 0.140 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2016 | 16 | 0.140 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 243 | 0.140 |
Why?
|
Pilot Projects | 1 | 2017 | 218 | 0.140 |
Why?
|
Specimen Handling | 1 | 2016 | 20 | 0.130 |
Why?
|
Overweight | 3 | 2007 | 269 | 0.130 |
Why?
|
Antihypertensive Agents | 1 | 2017 | 161 | 0.130 |
Why?
|
Risk | 2 | 2015 | 516 | 0.130 |
Why?
|
Medical Records | 1 | 2015 | 100 | 0.130 |
Why?
|
Health Surveys | 1 | 2016 | 260 | 0.120 |
Why?
|
Inpatients | 1 | 2015 | 81 | 0.120 |
Why?
|
Hypoglycemic Agents | 1 | 2017 | 268 | 0.120 |
Why?
|
Outpatients | 1 | 2015 | 107 | 0.120 |
Why?
|
Prognosis | 3 | 2015 | 606 | 0.120 |
Why?
|
Self Efficacy | 1 | 2014 | 68 | 0.120 |
Why?
|
Cardiovascular Agents | 1 | 2014 | 24 | 0.110 |
Why?
|
Patient Advocacy | 1 | 2013 | 13 | 0.110 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2013 | 10 | 0.110 |
Why?
|
Depressive Disorder, Major | 1 | 2015 | 124 | 0.110 |
Why?
|
Observer Variation | 1 | 2013 | 37 | 0.110 |
Why?
|
Utilization Review | 1 | 2013 | 53 | 0.110 |
Why?
|
Selection Bias | 1 | 2013 | 19 | 0.110 |
Why?
|
Observation | 1 | 2013 | 23 | 0.110 |
Why?
|
Patient Care Planning | 1 | 2013 | 52 | 0.110 |
Why?
|
Health Promotion | 1 | 2016 | 280 | 0.110 |
Why?
|
Confidence Intervals | 3 | 2013 | 237 | 0.110 |
Why?
|
Societies, Medical | 1 | 2013 | 74 | 0.110 |
Why?
|
Confounding Factors (Epidemiology) | 1 | 2013 | 86 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2013 | 24 | 0.110 |
Why?
|
Counseling | 1 | 2015 | 189 | 0.110 |
Why?
|
Continuity of Patient Care | 2 | 2011 | 105 | 0.110 |
Why?
|
Patient Preference | 1 | 2013 | 48 | 0.110 |
Why?
|
Effect Modifier, Epidemiologic | 1 | 2012 | 9 | 0.110 |
Why?
|
Recurrence | 1 | 2013 | 186 | 0.110 |
Why?
|
Survival Analysis | 1 | 2013 | 215 | 0.110 |
Why?
|
Hypertension | 1 | 2017 | 500 | 0.100 |
Why?
|
Translational Medical Research | 1 | 2012 | 35 | 0.100 |
Why?
|
Ovariectomy | 1 | 2012 | 9 | 0.100 |
Why?
|
Outcome and Process Assessment (Health Care) | 1 | 2012 | 102 | 0.100 |
Why?
|
Genetic Counseling | 1 | 2012 | 26 | 0.100 |
Why?
|
Clinical Coding | 1 | 2011 | 11 | 0.100 |
Why?
|
Drug Administration Schedule | 2 | 2012 | 98 | 0.100 |
Why?
|
Program Evaluation | 1 | 2012 | 223 | 0.100 |
Why?
|
Ovarian Neoplasms | 1 | 2012 | 49 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 140 | 0.100 |
Why?
|
Specialization | 1 | 2011 | 24 | 0.100 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2012 | 322 | 0.090 |
Why?
|
Treatment Outcome | 4 | 2015 | 1259 | 0.090 |
Why?
|
False Positive Reactions | 1 | 2010 | 26 | 0.090 |
Why?
|
Longitudinal Studies | 3 | 2020 | 710 | 0.090 |
Why?
|
Depression | 1 | 2015 | 502 | 0.090 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2017 | 748 | 0.090 |
Why?
|
Anti-Ulcer Agents | 1 | 2009 | 5 | 0.080 |
Why?
|
Medication Adherence | 1 | 2012 | 244 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2011 | 244 | 0.080 |
Why?
|
Phenotype | 2 | 2020 | 149 | 0.080 |
Why?
|
Antineoplastic Agents | 1 | 2009 | 59 | 0.080 |
Why?
|
Telephone | 3 | 2017 | 161 | 0.080 |
Why?
|
Health Behavior | 2 | 2012 | 359 | 0.080 |
Why?
|
Prospective Studies | 1 | 2012 | 1267 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2009 | 167 | 0.080 |
Why?
|
Carcinoma, Lobular | 1 | 2007 | 10 | 0.080 |
Why?
|
Sigmoidoscopy | 3 | 2013 | 65 | 0.070 |
Why?
|
Pregnancy | 2 | 2023 | 1494 | 0.070 |
Why?
|
Prolactin | 1 | 2007 | 4 | 0.070 |
Why?
|
Medicare | 2 | 2017 | 202 | 0.070 |
Why?
|
Multivariate Analysis | 1 | 2007 | 568 | 0.060 |
Why?
|
Outcome Assessment (Health Care) | 2 | 2017 | 228 | 0.060 |
Why?
|
Texas | 1 | 2025 | 35 | 0.060 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 38 | 0.060 |
Why?
|
Menstrual Cycle | 1 | 2004 | 5 | 0.060 |
Why?
|
Androgens | 1 | 2004 | 12 | 0.060 |
Why?
|
Testosterone | 1 | 2004 | 22 | 0.060 |
Why?
|
Probability | 1 | 2004 | 79 | 0.060 |
Why?
|
Adipose Tissue | 1 | 2004 | 58 | 0.060 |
Why?
|
Parity | 1 | 2004 | 74 | 0.060 |
Why?
|
Aromatase | 1 | 2004 | 7 | 0.060 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2004 | 5 | 0.060 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2004 | 6 | 0.060 |
Why?
|
Gonadal Steroid Hormones | 1 | 2004 | 26 | 0.060 |
Why?
|
Age Distribution | 1 | 2004 | 246 | 0.060 |
Why?
|
Polymorphism, Genetic | 1 | 2004 | 62 | 0.060 |
Why?
|
Office Visits | 2 | 2016 | 80 | 0.060 |
Why?
|
Obesity | 2 | 2007 | 837 | 0.050 |
Why?
|
Papanicolaou Test | 1 | 2022 | 37 | 0.050 |
Why?
|
Prostate-Specific Antigen | 1 | 2022 | 75 | 0.050 |
Why?
|
California | 2 | 2019 | 2284 | 0.050 |
Why?
|
Self Report | 2 | 2013 | 251 | 0.050 |
Why?
|
Body Mass Index | 4 | 2007 | 958 | 0.050 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2020 | 15 | 0.040 |
Why?
|
Data Warehousing | 1 | 2020 | 3 | 0.040 |
Why?
|
DNA Methylation | 1 | 2020 | 41 | 0.040 |
Why?
|
Pandemics | 1 | 2022 | 287 | 0.040 |
Why?
|
Weight Loss | 1 | 2022 | 303 | 0.040 |
Why?
|
Medical History Taking | 1 | 2019 | 35 | 0.040 |
Why?
|
Mutation | 1 | 2020 | 128 | 0.040 |
Why?
|
Financial Support | 1 | 2019 | 5 | 0.040 |
Why?
|
Biopsy | 1 | 2019 | 74 | 0.040 |
Why?
|
Demography | 1 | 2019 | 101 | 0.040 |
Why?
|
Age of Onset | 1 | 2019 | 79 | 0.040 |
Why?
|
Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 2 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2018 | 57 | 0.040 |
Why?
|
Attitude to Health | 1 | 2019 | 164 | 0.040 |
Why?
|
Sulfonylurea Compounds | 1 | 2017 | 24 | 0.040 |
Why?
|
Metformin | 1 | 2017 | 57 | 0.040 |
Why?
|
Insulin | 1 | 2017 | 205 | 0.030 |
Why?
|
Aftercare | 1 | 2016 | 49 | 0.030 |
Why?
|
Idaho | 1 | 2013 | 24 | 0.030 |
Why?
|
Sex Factors | 1 | 2015 | 643 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2013 | 80 | 0.030 |
Why?
|
Aromatase Inhibitors | 1 | 2012 | 32 | 0.030 |
Why?
|
Treatment Refusal | 1 | 2012 | 33 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2014 | 248 | 0.020 |
Why?
|
Regression Analysis | 1 | 2012 | 297 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2011 | 159 | 0.020 |
Why?
|
Nursing Care | 1 | 2010 | 4 | 0.020 |
Why?
|
Nursing Staff, Hospital | 1 | 2010 | 11 | 0.020 |
Why?
|
Sample Size | 1 | 2010 | 29 | 0.020 |
Why?
|
Quality Control | 1 | 2010 | 45 | 0.020 |
Why?
|
Allied Health Personnel | 1 | 2010 | 11 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 368 | 0.020 |
Why?
|
Continental Population Groups | 1 | 2012 | 302 | 0.020 |
Why?
|
Data Collection | 1 | 2010 | 256 | 0.020 |
Why?
|
Chronic Disease | 1 | 2011 | 428 | 0.020 |
Why?
|
Long-Term Care | 1 | 2007 | 22 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2007 | 166 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 2004 | 4 | 0.010 |
Why?
|
Catechol O-Methyltransferase | 1 | 2004 | 1 | 0.010 |
Why?
|
Cytochrome P-450 CYP1B1 | 1 | 2004 | 2 | 0.010 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2007 | 375 | 0.010 |
Why?
|
Alleles | 1 | 2004 | 84 | 0.010 |
Why?
|
Genotype | 1 | 2004 | 227 | 0.010 |
Why?
|
Body Weight | 1 | 2004 | 219 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2004 | 205 | 0.010 |
Why?
|